Skip to Content
Merck
  • Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc.

Calcineurin-mediated dephosphorylation enhances the stability and transactivation of c-Myc.

Scientific reports (2023-08-13)
Takahiro Masaki, Makoto Habara, Shunsuke Hanaki, Yuki Sato, Haruki Tomiyasu, Yosei Miki, Midori Shimada
ABSTRACT

c-Myc, a transcription factor, induces cell proliferation and is often aberrantly or highly expressed in cancers. However, molecular mechanisms underlying this aberrantly high expression remain unclear. Here, we found that intracellular Ca2+ concentration regulates c-Myc oncoprotein stability. We identified that calcineurin, a Ca2+-dependent protein phosphatase, is a positive regulator of c-Myc expression. Calcineurin depletion suppresses c-Myc targeted gene expression and c-Myc degradation. Calcineurin directly dephosphorylates Thr58 and Ser62 in c-Myc, which inhibit binding to the ubiquitin ligase Fbxw7. Mutations within the autoinhibitory domain of calcineurin, most frequently observed in cancer, may increase phosphatase activity, increasing c-Myc transcriptional activity in turn. Notably, calcineurin inhibition with FK506 decreased c-Myc expression with enhanced Thr58 and Ser62 phosphorylation in a mouse xenograft model. Thus, calcineurin can stabilize c-Myc, promoting tumor progression. Therefore, we propose that Ca2+ signaling dysfunction affects cancer-cell proliferation via increased c-Myc stability and that calcineurin inhibition could be a new therapeutic target of c-Myc-overexpressing cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Calcineurin Inhibitor VIII, CN585, The Calcineurin Inhibitor VIII, CN585, also referenced under CAS 1213234-31-1, controls the biological activity of Calcineurin. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
SKU
Pack Size
Availability
Price
Quantity